FerroptoCure
Tokyo, Japan· Est.
A clinical-stage biotech developing ferroptosis-inducing drugs to treat cancer by targeting antioxidant pathways like xCT.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $10.2M
AI Company Overview
A clinical-stage biotech developing ferroptosis-inducing drugs to treat cancer by targeting antioxidant pathways like xCT.
Oncology
Technology Platform
Platform for developing small-molecule therapeutics that induce ferroptosis by targeting and overcoming resistance in cancer antioxidant pathways, primarily the cystine/glutamate transporter (xCT).
Opportunities
The ferroptosis field is a high-growth area in oncology with potential to treat therapy-resistant cancers; long-term opportunities exist in expanding into neurodegenerative diseases and metabolic disorders like NASH.
Risk Factors
High clinical risk as ferroptosis induction is a novel therapeutic mechanism with unproven efficacy and safety profile in humans; faces competition from other biotechs targeting ferroptosis pathways like GPX4.
Competitive Landscape
Competes with other biotechs targeting ferroptosis (e.g., GPX4 inhibitors). Differentiation lies in its deep foundational research on xCT and resistance mechanisms (ALDH, CD44v) and prior clinical POC with sulfasalazine.